Insider Selling: Tempus AI (NASDAQ:TEM) CEO Sells 166,250 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky sold 166,250 shares of the business’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $74.10, for a total transaction of $12,319,125.00. Following the completion of the transaction, the chief executive officer owned 9,008,033 shares of the company’s stock, valued at approximately $667,495,245.30. This trade represents a 1.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Tempus AI Stock Up 1.0%

Shares of Tempus AI stock traded up $0.78 during trading hours on Tuesday, reaching $76.84. 4,884,340 shares of the company were exchanged, compared to its average volume of 11,165,074. The firm has a market cap of $13.67 billion, a PE ratio of -64.57 and a beta of 4.86. The stock’s fifty day moving average is $83.45 and its 200 day moving average is $72.29. Tempus AI, Inc. has a 1 year low of $31.36 and a 1 year high of $104.32. The company has a debt-to-equity ratio of 2.45, a quick ratio of 3.12 and a current ratio of 3.28.

Tempus AI (NASDAQ:TEM) last released its earnings results on Tuesday, November 4th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.05. Tempus AI had a negative return on equity of 73.21% and a negative net margin of 18.45%.The firm had revenue of $334.21 million during the quarter, compared to analysts’ expectations of $328.89 million. During the same period in the previous year, the firm posted ($0.46) EPS. Tempus AI’s revenue for the quarter was up 84.7% on a year-over-year basis. Tempus AI has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Tempus AI, Inc. will post -6.15 earnings per share for the current year.

Institutional Trading of Tempus AI

Several institutional investors have recently modified their holdings of the stock. Cranbrook Wealth Management LLC purchased a new position in shares of Tempus AI in the 3rd quarter valued at $25,000. Concord Wealth Partners lifted its position in Tempus AI by 308.0% in the second quarter. Concord Wealth Partners now owns 408 shares of the company’s stock valued at $26,000 after acquiring an additional 308 shares during the last quarter. JPL Wealth Management LLC acquired a new position in Tempus AI in the third quarter valued at $26,000. GAMMA Investing LLC purchased a new position in shares of Tempus AI during the third quarter worth about $28,000. Finally, Allworth Financial LP increased its position in shares of Tempus AI by 5,000.0% during the second quarter. Allworth Financial LP now owns 459 shares of the company’s stock worth $29,000 after purchasing an additional 450 shares in the last quarter. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on TEM. TD Cowen lowered shares of Tempus AI from a “buy” rating to a “hold” rating and set a $88.00 target price on the stock. in a research note on Tuesday, October 21st. BTIG Research boosted their price target on shares of Tempus AI from $96.00 to $105.00 and gave the stock a “buy” rating in a report on Tuesday. Guggenheim increased their price objective on shares of Tempus AI from $80.00 to $95.00 and gave the company a “buy” rating in a research report on Friday, September 26th. Canaccord Genuity Group decreased their price objective on shares of Tempus AI from $110.00 to $95.00 and set a “buy” rating for the company in a research report on Wednesday, November 5th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Tempus AI in a report on Wednesday, October 8th. Seven analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $80.75.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.